参考文献/References:
[1]Benjamin EJ,Muntner P,Alonso A,et al. Heart Disease and stroke statistics-2019 update:a report from the American Heart Association [J]. Circulation,2019,139(10):e56-e528.
[2]Kasselman LJ,Vernice NA,Deleon J,et al.The gut microbiome and elevated cardiovascular risk in obesity and autoimmunity[J].Atherosclerosis,2018,271:203-213.
[3]Janeiro MH,Ramírez MJ,Milagro FI,et al. Implication of trimethylamine N-oxide (TMAO) in disease:potential biomarker or new therapeutic target[J].Nutrients,2018,10(10).pii:E1398
[4]Mansoor JK,Schelegle ES,Davis CE,et al. Analysis of volatile compounds in exhaled breath condensate in patients with severe pulmonary arterial hypertension[J]. PLoS One,2014,9(4):e95331..
[5]Li T,Chen Y,Gua C,et al.Elevated circulating trimethylamine N-oxide levels contribute to endothelial dysfunction in aged rats through vascular inflammation and oxidative stress[J].Front Physiol,2017,8:350.
[6]Chen K,Zheng X,Feng M,et al.Gut microbiota-dependent metabolite trimethylamine N-oxide contributes to cardiac dysfunction in western diet-induced obese mice[J].Front Physiol,2017,8:139.
[7]Wang Z,Klipfell E,Bennett BJ,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57-63.
[8]Zheng L,Zheng J,Xie Y,et al.Serum gut microbe-dependent trimethylamine N-oxide improves the prediction of future cardiovascular disease in a community-based general population[J].Atherosclerosis,2019,280:126-131.
[9]Tan Y,Sheng Z,Zhou P,et al.Plasma trimethylamine N-oxide as a novel biomarker for plaque rupture in patients with ST-segment-elevation myocardial infarction[J].Circ Cardiovasc Interv,2019,12(1):e007281.
[10]Bogiatzi C,Gloor G,Allen-Vercoe E,et al.Metabolic products of the intestinal microbiome and extremes of atherosclerosis[J].Atherosclerosis,2018,273:91-97.
[11]Tang WH,Wang Z,Levison BS,et al.Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk[J].N Engl J Med,2013,368(17):1575-1584.
[12]Yu D,Shu XO,Rivera PES,et al.Urinary levels of trimethylamine-N-oxide and incident coronary heart disease:a prospective investigation among urban chinese adults[J].J Am Heart Assoc,2019,8(1):e010606.
[13]Zhong Z,Liu J,Zhang Q,et al.Targeted metabolomic analysis of plasma metabolites in patients with coronary heart disease in southern China[J].Medicine(Baltimore),2019,98(7):e14309.
[14]Ding L,Chang M,Guo Y,et al.Trimethylamine-N-oxide(TMAO)-induced atherosclerosis is associated with bile acid metabolism[J].Lipids Health Dis,2018,17(1):286.
[15]Geng J,Yang C,Wang B,et al.Trimethylamine N-oxide promotes atherosclerosis via CD36-dependent MAPK/JNK pathway [J].Biomed Pharmacother,2018,97:941-947.
[16]Seldin MM,Meng Y,Qi H,et al.Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-κB[J].J Am Heart Assoc,2016,5(2).
[17]Sun X,Jiao X,Ma Y,et al.Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIPNLRP3 inflammasome[J].Biochem Biophys Res Commun,2016,481(1-2):63-70 .
[18]Ma G,Pan B,Chen Y,et al.Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion[J].Biosci Rep,2017,37(2).pii:BSR20160244
[19]Wang Z,Zhao Y.Gut microbiota derived metabolites in cardiovascular health and disease[J].Protein Cell,2018, 9(5):416-431.
[20]Hayashi T,Irino Y,Toh R,et al.Gut microbiome and plasma microbiome-related metabolites in patients with decompensated and compensated heart failure[J].Circ J,2018,83(1):182-192.
[21]Tang WW,Wang Z,Fan Y,et al.Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure:refining the gut hypothesis[J].J Am Coll Cardiol,2014,64(18):1908-1914.
[22]Toru Suzuki,Yoshiyuki Yazaki,Adriaan A Voors,et al.Association with outcomes and response to treatment of trimethylamine N-oxide in heart failure(from BIOSTAT-CHF)[J].Eur J Heart Fail,2019,21(7):887-890.
[23]Sandek A,Bauditz J,Swidsinski A,et al.Altered intestinal function in patients with chronic heart failure[J].J Am Coll Cardiol,2007,50(16):1561-1569.
[24]Chioncel O,Ambrosy AP.Trimethylamine N-oxide and risk of heart failure progression:marker or mediator of disease[J].Eur J Heart Fail,2019,21(7):887-890.
[25]Ufnal M,Jazwiec R,Dadlez M,et al.Trimethylamine-N-oxide:a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin ii in rats[J].Can J Cardiol,2014,30(12):1700-1705.
[26]Liu M,Han Q,Yang J.Trimethylamine-N-oxide (TMAO) increased aquaporin-2 expression in spontaneously hypertensive rats[J].Clin Exp Hypertens,2019,41(4):312-322.
[27]Svingen GFT,Hui Z,Ueland PM,et al.Increased plasma trimethylamine-N-oxide is associated with incident atrial fibrillation[J].Int J Cardiol,2018,267:100-106.
[28]Sharon G,Sampson T,Geschwind D,et al.The central nervous system and the gut microbiome[J].Cell,2016,167(4): 915-932.
[29]Yu L,Meng G,Huang B,et al.A potential relationship between gut microbes and atrial fibrillation:trimethylamine N-oxide,a gut microbe-derived metabolite,facilitates the progression of atrial fibrillation[J].Int J Cardiol,2018,255:92-98..
[30]Panagiotis K,Letsas KP,Gary T,et al.Inflammation and atrial fibrillation:a comprehensive review[J].J Arrhythm,2018,34(4):394-401.
[31]Wei S,Yu Y,Zhang Z,et al.Proinflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat[J].Hypertension (Baltimore),2015,65(5):1126-33.
[32]O’Malley D,Liston M,Hyland NP,et al.Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism[J].Am J Physiol Gastrointest Liver Physiol,2011,300(2):241-252.
[33]Petrie CN,Armitage MN,Kawaja MD.Myenteric expression of nerve growth factor and the p75 neurotrophin receptor regulate axonal remodeling as a consequence of colonic inflammation in mice[J].Exp Neurol,2015,271:228-240.
[34]Li Z,Wu Z,Yan J,et al.Gut microbe-derived metabolite trimethylamine N-oxide induces cardiac hypertrophy and fibrosis[J].Lab Invest,2019,99(3):346-357.
[35]Zhang H,Meng J,Yu H.Trimethylamine N-oxide supplementation abolishes the cardioprotective effects of voluntary exercise in mice fed a western diet[J].Front Physiol,2017,8:944.
[36]Jin M,Qian Z,Yin J,et al.The role of intestinal microbiota in cardiovascular disease[J].J Cell Mol Med,2019,23(4):2343-2350.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(1):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(1):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(1):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(1):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(1):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]